Acute effects of etidronate on glucocorticoid-induced bone degradation

Rheumatology

Volumn 39, Issue 5, 2000, Pages 523-529

  Struijs, A ^a,e   Smals, A ^b   De Witte, S A ^a   Hackeng, W H L ^c   Mulder, H ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Praktijk V Laboratorium Diagnostiek   (Netherlands)

^d Site Management Organisation   (Netherlands)

^e NONE   (Netherlands)

Author keywords

Bisphosphonate; Bone markers; Calcium metabolism; Corticosteroid; Etidronate; Glucocorticoid; Osteoporosis; Prednisone

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIUM; CREATININE; ETIDRONIC ACID; GLUCOCORTICOID; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; PREDNISONE; PROCOLLAGEN C PROTEINASE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; TEMPORAL ARTERITIS;

EID: 0034081327     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/39.5.523     Document Type: Article

References (42)

1. Meunier PJ. Is steroid-induced osteoporosis preventable? N Engl J Med 1993;328:1781-2.
2. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and the risk of hip fracture. Ann Rheum Dis 1995;54:49-52.
3. Lems WF, Jahangier ZN, Jacobs JWG, Bijlsma JWJ. Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin Exp Rheum 1995; 13:293-7.
4. Need AG, Philcox JC, Hartley TF, Nordin BE. Calcium metabolism and osteoporosis in corticosteroid-treated postmenopausal woman. Aust NZ J Med 1986;16:341.
5. Colette C, Monnier L, Herbute NP, Blotman F, Miruoze J. Calcium absorption in corticoid treated subjects: effects of single oral dose of calcitriol. Horm Metab Res 1987;19:335-8.
6. Findling JW, Adams NS, Lemann J, Gray RW, Thomas CJ, Tyrrell JB. Vitamin D metabolites and parathyroid hormone in Cushing's syndrome: relationship to calcium and phosphorus homeostasis. J Clin Endocrinol Metab 1982;54:1039-44.
7. Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983;32:151-6.
8. Lukert BP, Adams JS. Calcium and phosphorus homeostasis in man: Effect of corticosteroids. Arch Int Med 1976;136:1249-53.
9. Gennari C, Imbimbo B, Montagnani M, Bernini M, Avioli LV. Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int 1984;36:245-52.
10. Delany AM, Dong Y, Canalis E. Mechanisms of glucocorticoid action in bone cells. J Cell Biochem 1994;56: 295-302.
11. Chevalley T, Strong DD, Mohan S, Baylink DJ, Linkhart TH. Evidence for a role for insulin-like growth factor binding proteins in glucocorticoid inhibition of normal human osteoblast-like cell proliferation. Eur J Endocrinol 1996;134:591-601.
12. Morrison NA, Shine J, Fragonas JC. 1.25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science 1989;146: 1158-61.
13. Lems WF, Gerrits MI, Jacobs JWG, Vugt RM, van Rijn HJM, Bijlsma JWJ. Changes in markers of bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis 1996;55:288-93.
14. Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989;4:137-41.
15. Sambrook P, Birmingham J, Kelly P et al. Prevention of corticosteroid osteoporosis. N Engl J Med 1993;328: 1747-52.
16. Murphy S, Khaw KT, Cassidy A, Compston JE. Sex hormones and bone mineral density in elderly men. Bone Miner 1993:20:133-40.
17. Bagatell CJ, Bremner WJ. Androgens in men - uses and abuses. N Engl J Med 1996;334:707-14.
18. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988;1:143-6.
19. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992;7:1063-9.
20. Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991;49:71-6.
21. Mulder H, Struijs A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33:348-50.
22. Struijs A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235-42.
23. Adachi JD, Bensen WG, Brown J et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
24. Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
25. Hackeng WHL, Lips P, Netelenbos C, Lips CJM. Clinical implications of estimation of intact parathyroid hormone (PTH) versus total immunoreactive PTH in normal subjects and hyperparathyroid patients. J Clin Endocrinol Metab 1986;63:447-53.
26. Lems WF, Jacobs JWG, van den Brink HR, van Rijn HJM, Bijlsma JWJ. Transient decrease in osteocalcin and markers of collagen type 1 formation during corticosteroid pulse therapy. Br J Rheum 1993;32:787-90.
27. 3, parathyroid hormone and glucocorticoids. Metab Bone Dis Rel Res 1984;5:229-34.
28. Gram J, Junker P, Nielsen HK, Bollerslev J. Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men. Bone 1998;23:297-302.
29. Lems WF, Jacobs JWG, van Rijn HJM, Bijlsma JWJ. Changes in calcium and bone metabolism during treatment with low dose prednisone in young, healthy, male volunteers. Clin Rheumatol 1995;14:420-4.
30. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R. Highdose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994;9:1097-1105.
31. Barnes PJ, Pedersen S, Busse W. Efficacy and safety of inhaled corticosteroids. Am J Resp Crit Care Med 1998;157:S1-S53.
32. Bijvoet OLM, Frijlink K, Jie K et al. APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum 1980;23:1143-1203.
33. 3. In: Veis A. ed. The chemistry and biology of mineralized connective tissues. New York: Elsevier/North Holland, 1981:327-35.
34. Tobias JH, Laversuch CJ, Chambers TJ, Gallagher AC. Aminohexane bisphosphonate suppresses bone turnover in post menopausal women more rapidly than oestrogengestagen therapy. Br J Rheumatol 1996;35:636-41.
35. Papapoulos SD, Frohlich M, Mudde AH, Harinck HIJ, Berg H, Bijvoet OLM. Serum osteocalcin in Paget's disease of bone: Basal concentrations and response to bisphosphonate treatment. J Clin Endocrinol Metab 1987;65:89-94.
36. Koster JC, Hackeng WHL, Mulder H. Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol 1996;51:145-7.
37. Boonekamp PM, vd Wee-Pals LJA, v Wijk-v Lennep MML, Thesingh CW, Bijvoet OLM. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986;1:27-39.
38. Adami S, Frijlink WB, Bijvoet OLM, O'Riordan JHL, Clemens TL, Papapoulos SE. Regulation of calcium absorption by 1,25-dihydroxyvitamin D. Studies of the effect of a bisphosphonate treatment. Calcif Tissue Int 1982;34:317-20.
39. Papapoulos SE, Harinck HIJ, Bijvoet OLM, Gleed JH, Fraher LJ, O'Riordan JHL. Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin metabolites in normocalcaemic and hypercalcaemic patients treated with APD. Bone Miner 1986;1:69-78.
40. 3-induced 24-hydroxylase activity in osteoblast-like cells: initiation of the c24-oxidation pathway. Bone 1997;20:237-43.
41. 3 inhibits osteocalcin expression in mouse through an indirect mechanism. J Biol Chem 1997;272:110-6.
42. Lian JB, Shalhoub V, Aslam F, Frenkel B, Green J, Hamrah M et al. Species-specific glucocorticoid and 1,25 dihydroxyvitamin D3 responsiveness in mouse mc3t3-E1 osteoblast: dexamethasone inhibits osteoblast differentiation and vitamin D down-regulates osteocalcin gene expression. Endocrinology 1997;138:2117-27.